CollabRx Retains Hayden IR to Develop Strategic Investor Relations Program

CollabRx Retains Hayden IR to Develop Strategic Investor Relations Program

SAN FRANCISCO, July 25, 2013 (GLOBE NEWSWIRE) -- CollabRx, Inc. (Nasdaq:CLRX),
a data analytics company focused on informing clinical decision making in
molecular medicine, announced it has engaged Hayden IR, a 15-year-old, highly
recognized, national investor relations firm, to raise the visibility of
CollabRx and strengthen its relationships with the investment community

"Over the past year, we have strengthened our financial position and
transformed our overall business from development stage to commercialization
phase, with our first substantial revenue coming in the fourth quarter of our
fiscal 2013," said Thomas R. Mika, Chief Executive Officer of CollabRx. "This
is an important foundation as we begin our new fiscal year generating revenue,
expanding internationally, and adding partnerships to accelerate the adoption
of our commercial offerings and grow our recurring revenue. We believe it is
an appropriate time to retain a national investor relations firm to help us
target and expand our investor audience and ensure we are communicating
effectively with Wall Street. We look forward to working with the team of
professionals at Hayden IR to execute this important goal."

With offices in New York, Phoenix, Minneapolis and San Diego, Hayden IR
provides a comprehensive range of investor relations services to a growing
list of clients. For more than a decade, Hayden IR has been a recognized
leader in driving market recognition and creating sustainable competitive
advantages for more than 100 micro- and small-cap companies. Hayden delivers
expertise and professionalism in such areas as investor management,
relationship building, awareness campaigns, online presence and corporate
identity.

Brett Maas, Managing Partner of Hayden IR, added, "CollabRx represents a
compelling opportunity as it transitions from the development stage into the
commercialization phase. The Company has a diverse, scalable business model,
with multiple revenue sources including Software-as-a Service (SaaS), 90%-plus
gross margins, virtually no CapEx, and approximately $14 million invested in
the platform to date. CollabRx has an outstanding reputation; it is growing
the number of strong partners it serves with its technology platform,
increasing revenue per client, and expanding the portfolio of products
provided to individual clients through the cross-marketing of complementary
functions."

Mr. Maas continued, "The Company's addressable opportunity includes the $18
billion genetic sequencing market and $1.5 billion next generation sequencing
(NGS) market. 1.6 million individuals are diagnosed with cancer annually, 12
million in the United States have or have had cancer, and clinical NGS testing
for cancer is projected to grow at 100% per annum. CollabRx is at the
convergence of mega trends including genomics, precision medicine, web and
mobile apps, and big data analytics. CollabRx efficiently operates at the
intersection of these mega trends by combining its technology platform with
artificial intelligence (AI) based expert systems that enable the Company to
contextualize large quantities of information using insights from leading
clinical practitioners based at prestigious academic-based hospitals. The
Company is democratizing "thought-leader" medicine, as it begins its
commercialization effort with leading partners, positioned as virtually the
only pure-play public company in the sector. The team at Hayden IR looks
forward to articulating this opportunity to the professional investment
community."

About CollabRx

CollabRx, Inc. (Nasdaq:CLRX) is a recognized leader in cloud-based expert
systems to inform healthcare decision-making. CollabRx uses information
technology to aggregate and contextualize the world's knowledge on
genomics-based medicine with specific insights from the nation's top cancer
experts, starting with the area of greatest need: advanced cancers in patients
who have effectively exhausted the standard of care. More information may be
obtained at http://www.collabrx.com.

CollabRx Safe Harbor Statement

This press release includes forward-looking statements about CollabRx's
anticipated results that involve risks and uncertainties. Some of the
information contained in this press release, including, but not limited to,
statements as to industry trends and CollabRx's plans, objectives,
expectations and strategy for its business, contains forward-looking
statements that are subject to risks and uncertainties that could cause actual
results or events to differ materially from those expressed or implied by such
forward-looking statements. Any statements that are not statements of
historical fact are forward-looking statements. When used, the words
"believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and
the like, and/or future tense or conditional constructions ("will," "may,"
"could," "should," etc.), or similar expressions, identify certain of these
forward-looking statements. Important factors which could cause actual results
to differ materially from those in the forward-looking statements are detailed
in filings made by CollabRx with the Securities and Exchange Commission.
CollabRx undertakes no obligation to update or revise any such forward-looking
statements to reflect subsequent events or circumstances.

CONTACT: Investor Relations Contacts:
        
         Thomas R. Mika, CEO
         CollabRx, Inc.
         415-248-5350
         or
         James Carbonara, Regional Vice President
         Hayden IR
         646-755-7412
         James@haydenir.com

CollabRx, Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.